The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces January 2013 Investor Conference Presentations

Thursday, December 20, 2012

Regeneron Announces January 2013 Investor Conference Presentations09:30 EST Thursday, December 20, 2012TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:Goldman Sachs Healthcare CEOs Unscripted:  A View from the Top on Thursday, January 3, 2013.  The session is scheduled for 3:15 p.m. Eastern Time. 31st Annual J. P. Morgan Healthcare Conference on Tuesday, January 8, 2013.  The presentation is scheduled for 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.                       Peter DworkinInvestor Relations                                Corporate Communications                            914.847.7799                                           914.847.7640              michael.aberman@regeneron.com             peter.dworkin@regeneron.com SOURCE Regeneron Pharmaceuticals, Inc.